Published in Cancer Weekly, December 7th, 2004
This premarketing phase IV study is a multicenter, open-label study that will measure clinical efficacy based on local tumor control through a 6-month post treatment period and assess local and systemic safety and tolerance. It will also evaluate pharmacoeconomic benefits including reductions in surgical and hospital costs. Documenting...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.